Response to high-altitude triggers in seasonal asthmatics on and off inhaled corticosteroid treatment.
Asthma
High altitude
Inhaled corticosteroids
Triggers
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
20
01
2022
revised:
26
06
2022
accepted:
17
08
2022
entrez:
18
10
2022
pubmed:
19
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Due to the effects of climate change, winter sport enthusiasts will be increasingly forced to stay at higher altitudes. High altitude (HA) environmental factors such as cold temperature, physical exertion, and hypoxia with subsequent hypocapnia due to hyperventilation have been shown to induce bronchoconstriction. With bronchial asthma being highly prevalent, asthmatics also will be increasingly exposed to HA environment and might experience increasing symptoms. We analysed the effects of HA factors at around 2600 m a.s.l. (metres above sea level) on lung function in mild seasonal asthmatics while they were routinely off (January) and on (March, after start of lowland pollen season) low-dose inhaled corticosteroid (ICS) treatment (n = 10), and matched healthy controls (n = 11). Without inhaled corticosteroid (ICS) treatment mean FEV1 in asthmatics was 230 ml lower after exercise at HA compared to low altitude (LA, p < 0.05), while in healthy controls there was no significant difference. This decrease was mainly induced by cold and exercise at HA. During ICS treatment, this decrease was prevented. Methacholine response was reduced at HA compared to LA. The decrease of FEV1 in response to a combination of hypoxia, cold, and exercise is prevented by ICS treatment in mild, seasonal asthmatics. However, the FEV1 response to high altitude factors was overall small.
Sections du résumé
Background
UNASSIGNED
Due to the effects of climate change, winter sport enthusiasts will be increasingly forced to stay at higher altitudes. High altitude (HA) environmental factors such as cold temperature, physical exertion, and hypoxia with subsequent hypocapnia due to hyperventilation have been shown to induce bronchoconstriction. With bronchial asthma being highly prevalent, asthmatics also will be increasingly exposed to HA environment and might experience increasing symptoms.
Methods
UNASSIGNED
We analysed the effects of HA factors at around 2600 m a.s.l. (metres above sea level) on lung function in mild seasonal asthmatics while they were routinely off (January) and on (March, after start of lowland pollen season) low-dose inhaled corticosteroid (ICS) treatment (n = 10), and matched healthy controls (n = 11).
Results
UNASSIGNED
Without inhaled corticosteroid (ICS) treatment mean FEV1 in asthmatics was 230 ml lower after exercise at HA compared to low altitude (LA, p < 0.05), while in healthy controls there was no significant difference. This decrease was mainly induced by cold and exercise at HA. During ICS treatment, this decrease was prevented. Methacholine response was reduced at HA compared to LA.
Conclusions
UNASSIGNED
The decrease of FEV1 in response to a combination of hypoxia, cold, and exercise is prevented by ICS treatment in mild, seasonal asthmatics. However, the FEV1 response to high altitude factors was overall small.
Identifiants
pubmed: 36254181
doi: 10.1016/j.waojou.2022.100698
pii: S1939-4551(22)00074-6
pmc: PMC9513265
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100698Informations de copyright
© 2022 The Author(s).
Références
Chest. 1999 Dec;116(6):1653-8
pubmed: 10593790
Am J Respir Crit Care Med. 2000 Jan;161(1):309-29
pubmed: 10619836
J Asthma. 2010 Aug;47(6):614-9
pubmed: 20632917
J Appl Physiol (1985). 2010 Feb;108(2):256-65
pubmed: 19940099
Allergy. 2020 Jan;75(1):84-94
pubmed: 31267528
Eur Respir J. 1995 Nov;8(11):1842-6
pubmed: 8620949
Am J Respir Crit Care Med. 1997 Mar;155(3):1042-9
pubmed: 9116984
Allergy Asthma Immunol Res. 2016 Jul;8(4):312-8
pubmed: 27126724
Int J Sports Med. 2005 Apr;26(3):233-7
pubmed: 15776341
Thorax. 1996 Jun;51(6):582-4
pubmed: 8693437
Arch Intern Med. 2002 Nov 25;162(21):2421-6
pubmed: 12437400
Ann Allergy. 1986 Mar;56(3):226-8
pubmed: 3954163
Thorax. 2008 Oct;63(10):936-7
pubmed: 18820122
Respiration. 1997;64(6):444-9
pubmed: 9383820
Scand J Med Sci Sports. 2005 Oct;15(5):324-8
pubmed: 16181256
Eur Respir J. 1995 Sep;8(9):1488-93
pubmed: 8575573
J Appl Physiol Respir Environ Exerc Physiol. 1984 Aug;57(2):608-9
pubmed: 6469828
Am Rev Respir Dis. 1988 Oct;138(4):789-93
pubmed: 3059883
Thorax. 2013 Oct;68(10):906-13
pubmed: 23821393
J Appl Physiol. 1964 Jul;19:745-9
pubmed: 14195587